Report an error

Spotted something inaccurate in “Oral RAS Inhibitor Shows 35% Response Rate in Small Subgroup of Previously Treated Pancreatic Cancer Patients (Phase 1/2 Data)”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.